Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects (male or female) from 16 to 80 years of age at Visit 1, both inclusive~* Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method~* Subjects having at least 8 partial seizures (according to the 1981 ILAE classification) during the 8-Week Baseline Period with at least 2 partial seizures during each 4-week interval of the Baseline Period~* Subjects having at least 2 partial seizures whether or not secondary generalization per month during the 3 months preceding Visit 1~* Subjects uncontrolled while treated by 1 or 2 permitted concomitant antiepileptic drug \[AED\](s). Vagal Nerve Stimulation (VNS) is allowed and will be counted as a concomitant AED~Exclusion Criteria:~* Subject has history or presence of status epilepticus during the year preceding Visit 1 or during Baseline~* Subject is currently treated with levetiracetam~* Subject has taken levetiracetam within 90 days prior to Visit 1

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BRV 200 mg/day (Type: EXPERIMENTAL): 12 weeks Treatment Period: Subjects will receive BRV 200 mg/day~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 150 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 150 mg/day for 1 week followed by BRV 100 mg/day for 1 week, followed by BRV 50 mg/day for 1 week, followed by BRV 25 mg/day for 1 week followed by a Study Drug-Free Period
- Placebo (Type: PLACEBO_COMPARATOR): * 12 weeks Treatment Period: Subjects will receive Placebo~* 4 weeks Down-Titration Period: Subjects will receive Placebo
- BRV 50 mg/day (Type: EXPERIMENTAL): 12 weeks Treatment Period: Subjects will receive BRV 50 mg/day~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 50 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 25 mg/day for 1 week followed by Placebo for 3 weeks, followed by a Study Drug-Free Period

Based on this trial design, predict the completion outcome and termination type (if applicable).